Introduction
-It is stated that LDL and HDL are protective against sepsis. However, insufficient evidence for this statement is given. I would instead change "are" to "may be". Similarly, HDL-C "may be" protective against sepsis rather than "is" (see page 3, lines [16] [17] [18] [19] [20] [21] [22] Methods and Analysis -There is no comment on patients with hyper/hypothyroidism. Thyroid function has a significant impact on serum lipids. Critically ill patients with sepsis often present with derangements in thyroid function tests. Why are thyroid function tests TSH +/-T3/T4 not being measured or considered? -Can the authors please comment on why any tests of pancreatic function are not being performed (lipase/amylase) -I note patients receiving parenteral nutritional will be excluded, will the various fat contents and volume administered of enteral (PO/NG) feeds be recorded? -I would assume that knowing whether a patient is on lipid-altering drugs (e.g. statins) both prior to and during the study is very important and a potential confounder. Can the authors please comment on how patients on these (very popular) drugs will be managed?
-Can the authors comment on whether patients are likely to be on extra-corporeal circuits and, if so, whether it would be worth recording are any potential complications (e.g. from fat deposition) from the lipid emulsion on these circuits -Why have the authors chosen to look at all septic patients, rather than a more homogenous cohort (e.g. organism-specific or sitespecific)? Sepsis is a heterogeneous syndrome (rather than a single disease) that has a significant variation in the natural history dependent on the type of organism and the site.
REVIEWER
Charalampos Pierrakos CHU-Brugmann, Belgium REVIEW RETURNED 20-May-2019 GENERAL COMMENTS This is a very important pilot study where the appropriate dose of fish-oil containing lipid injectable emulsion as a treatment in sepsis or septic shock. The evaluation of the study would be made according to the efficiency to increase cholesterol levels without any toxic effects. The protocol is very well defined and the methodology is appropriate: Some minor points I would like to mention: 1) Please do not use two times the word hypothesis in the introduction. I think it causes some kind of confusion the prhase " we hypothesize based on previous work" as this is not the hypothesis of the study; the hypothesis of the study is very well defined in the last paragraph of introduction.
2) It is not mentioned what the authors will do with patients that are already in statins?
3) The factor of CVVH or ECMO has not been mentioned. I am wondering if in the phase I of the study should add some more patients who are already in CHVVH. There may be an unexpected interaction there. 4) I have some concerns about the term "acute drop" of cholesterol.
There are some patients that have already low levels of cholesterol. Should the authors exclude the malnourished patients? Maybe it is better not to talk about acute drop of cholesterol. 5) The results of the study expect to give the answer which is the optimal dose for increasing cholesterol but not which is the optimal cholesterol levels. I am wondering if this is a problem for a pilot study. Furthermore, possibly the baseline levels of cholesterol may play a role for the increase in cholesterol; maybe it is easier to see an increase in cholesterol when baseline values are very low compared to values when are abnormal but more near to normal limits. 6) I think the expected/needed number of patients that would be included in the phase II study should be also mentioned.
GENERAL COMMENTS
The authors propose that reduced HDL is causally related to mortality in sepsis, providing a justification for replacing this deficiency with a lipid emulsion in sepsis. The authors give the study design for a 2 center phase I/II clinical trial that includes a dose escalation safety component and a non-blinded randomized controlled trial. These will assess the effect of an intravenous fish-oil containing lipid emulsion on cholesterol levels in patients with sepsis. The authors provide two rationales for the proposed lipid emulsion intervention: I. Reduced cholesterol levels in sepsis has been associated with mortality; the intervention might increase cholesterol and thereby improve outcomes. II. Because the fish oil in the lipid emulsion contains omega-3 fatty acids, the emulsion may have beneficial anti-inflammatory effects.
The rationale and the proposed design of the study have important strengths and limitations. The study will be conducted in two centers, increasing the heterogeneity of patients enrolled in the study. However, the fact that both hospitals are part of the same medical system -University of Florida -make it only incrementally superior to a single centered trial. It is a randomized controlled trial, decreasing selection bias. However, it is not blinded to allocation of the intervention because blinding of a lipid infusion is not feasible.
One important methodological issue is that the authors do not describe how nutrition will be measured or compared in this trial.
Smoflipid is FDA approved as a parenteral source of nutrition. Even though the aim of Smoflipid in this study is to stabilize cholesterol, individuals receiving the experimental intervention will have likely have different nutritional requirements and fewer caloric needs, all else being equal, than controls. This potential confounder is not mentioned by the authors. I did not see a plan to measure or present the total nutrition received by both groups.
The evidence supporting the intervention in the background and discussion of this proposal can be criticized on several grounds. Other lipid emulsions have not been shown to improve outcomes in sepsis. For example, the LIPOS trial by Dellinger et al. . Failure of omega-3 to improve survival casts doubt on a benefit from anti-inflammatory omega-3 fatty acids in the present study. Of note, the rationale of the LIPOS trial was the ability of the lipid emulsion to bind endotoxin. This mechanism was also given in the present study. Unfortunately, the TLR4-endotoxin pathway has been extensively studied in sepsis and multiple interventions targeting that pathway have failed to improve outcomes (e.g. ACCESS trial of eritoran, Opal et al. JAMA 2016). In fact, no immunomodulatory intervention has ever durably improved survival in sepsis (e.g. Marshall 2014 Trends Mol Med).
Some specific issues are listed below:
Page 3 (top of page). Line 47. The assertion that "given that the study endpoint is numerical, the potential for bias is minimal" is incorrect. Systematic bias in the reporting of quantitative end-points is common and well-described. As an example, the post-hoc subgroup analysis (Parker et al. Crit Care 2014) referenced by the authors of this protocol was quantitative, but it might reflect publication bias -since a negative post hoc result would not have been deemed worthy of interest or publication. The lack of concealment of allocation in this study remains an important, though not insurmountable, source of bias in this study. Here the authors introduce another potential mechanism -anti-inflammatory effect of omega-3 fish oil. This is despite the fact that no intervention based on immunomodulation has ever decreased mortality in sepsis (e.g. Marshall 2014 Trends Mol Med).
Page 5. Line 16. refers to the critical early period of sepsis when cholesterol levels reach a nadir. The problem is that patients will vary in their time to presentation for treatment from onset of symptoms. We will not know where a given patient is relative to the nadir in cholesterol.
Page 12. Line 31. I assume that the authors will perform statistical tests on HDL, LDL, and TC, so there are at least three variables in the lipid panel. For secondary end points, the authors will include many more variables, including at least 7 inflammatory biomarkers. Is there a plan to correct for multiple comparisons? This should be mentioned in the analysis plan. The authors should check whether they intend to compare the change in mean lipid levels, implying individual patients will be measured multiply at planned time points. Importantly, since lipids are drawn at five planned collection times, limiting the analysis to only two time points leaves out the remaining three. Thus, the proposed analysis plan ignores data that they plan to collect and limits the ability to uncover a difference if it exists (increasing the likelihood of type II error). To avoid that problem the authors might use a statistical test more appropriate for repeated measures, such as a linear mixed model. Page 13. Line 14. "secondary analysis" should read a "secondary post-hoc analysis" or "secondary subgroup analysis that was not a pre-specified subgroup in the original study" Page 13 Line 18. " demonstrated mortality reductions," should be "showed potential reduced mortality." Page 13 Line 20. "Establishes" is way too strong a word. "Suggests" would be better.
Page 13 Line 26. The authors propose to use inclusion and exclusion criteria as proposed in the the Parker et al. (2014) subgroup analysis. The problem is that the LIPOS study used a different lipid emulsion, a detail that is not made clear in this proposal.
REVIEWER

Limin Feng
Clinical laboratory, Zhejiang University REVIEW RETURNED 20-Jun-2019
GENERAL COMMENTS
This manuscriptr is the results of the phase I and study II for for sepsis.
Major Revision: 1.
In manuscript, "16 patients will be enrolled in the phase I study to evaluate for optimal dose and DLTs."and" the phase II arm will include 24 patients randomized to one of the two doses of the study drug", Whether the sample size is sufficient? 2.
The two-center trial is not convincing enough.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1: Kerina Denny 1) In the first sentence, it is stated that there are no disease-specific treatments for sepsis. I would have thought antibiotics are a (the!) disease-specific treatment for sepsis.
RESPONSE: This wording has been removed and replaced with the definition of sepsis.
2) It is stated that LDL and HDL are protective against sepsis. However, insufficient evidence for this statement is given. I would instead change "are" to "may be". Similarly, HDL-C "may be" protective against sepsis rather than "is" (see page 3, lines [16] [17] [18] [19] [20] [21] [22] .
RESPONSE: This wording has been changed accordingly.
3) There is no comment on patients with hyper/hypothyroidism. Thyroid function has a significant impact on serum lipids. Critically ill patients with sepsis often present with derangements in thyroid function tests. Why are thyroid function tests TSH +/-T3/T4 not being measured or considered?
RESPONSE:
We appreciate the reviewer's point. Given a limited study budget, we will not have the resources to measure thyroid function tests on every patient; however, we will record history of thyroid disease and account for this in the final analysis. This has been added to the manuscript.
4)
Can the authors please comment on why any tests of pancreatic function are not being performed (lipase/amylase). RESPONSE: Pancreatitis must be a clinical concern of the treating clinicians. If the patient has an admitting diagnosis of pancreatitis, or if the treating teams have ordered an amylase/lipase and these values are abnormal, then the patient will be excluded from the study as per the exclusion criteria. 5) I note patients receiving parenteral nutritional will be excluded, will the various fat contents and volume administered of enteral (PO/NG) feeds be recorded?
RESPONSE:
We appreciate this comment. We have added that the type and formulation of enteral feeds, rate of administration, supplemental protein and dose, and lipid kilocalories will be recorded per day for the first 7 days.
6) I would assume that knowing whether a patient is on lipid-altering drugs (e.g. statins) both prior to and during the study is very important and a potential confounder. Can the authors please comment on how patients on these (very popular) drugs will be managed?
RESPONSE: Statin use (and the specific statin drug) will be recorded at the time enrollment but will not affect entry into the study. It will also be recorded as to whether or not the patient received a statin in the hospital. This has been added to the methods section. In our previous study of 88 patients with sepsis or septic shock, 1 baseline statin use vs. non-use was not significantly associated with differences in enrollment total cholesterol (108 vs 101, p = 0.35), HDL-C (30 vs. 27, p = 0.42), LDL-C (50 vs. 49, p = 0.92) or triglyceride levels (143 vs. 120, p = 0.16). It was also not associated with 48-hour differences for total cholesterol (104 vs. 102, p = 0.86), HDL-C (22 vs. 18, p = 0.32), LDL-C (51 vs. 54, p = 0.58), or triglycerides (153 vs. 154, p = 0.97). Given that the primary outcome is 48-hour total cholesterol level for the Phase II trial, and that nearly all statins (with the exception of pravachol) have a half-life of less than 24 hours, we do not anticipate this confounding our results.
7)
Can the authors comment on whether patients are likely to be on extra-corporeal circuits and, if so, whether it would be worth recording are any potential complications (e.g. from fat deposition) from the lipid emulsion on these circuits. RESPONSE: This is a good point, we appreciate the reviewer's comment. The lipid emulsion could deposit in the circuits, leading to both issues with oxygenation as well as failure to absorb the study drug. This has been added as an exclusion criteria.
8)
Why have the authors chosen to look at all septic patients, rather than a more homogenous cohort (e.g. organism-specific or site-specific)? Sepsis is a heterogeneous syndrome (rather than a single disease) that has a significant variation in the natural history dependent on the type of organism and the site.
RESPONSE:
We agree that sepsis is a heterogeneous condition. However, our preliminary data has identified trends in cholesterol levels and function across varying infection types and sites, and therefore our approach has some support. Also, the use of our cholesterol enrollment criteria, selects out a subpopulation of patients who are more homogeneous than the general population of septic patients. Additionally, this would limit the study in two ways. First, limiting to organism or infection type would make the study unfeasible for a two-site study. Given the enrollment criteria, set conservatively to ensure enrollment of potential responders while excluding patients who could experience an adverse event from the lipid emulsion, adding this additional criteria would make it impossible to do the study within the 2year time frame. Second, this would also limit the generalizability of the study results for most septic patients. Reviewer 2: Charalampos Pierrakos 1) Please do not use two times the word hypothesis in the introduction. I think it causes some kind of confusion the phrase " we hypothesize based on previous work" as this is not the hypothesis of the study; the hypothesis of the study is very well defined in the last paragraph of introduction.
RESPONSE: We appreciate the reviewers comment and have corrected this.
2) It is not mentioned what the authors will do with patients that are already in statins? RESPONSE: Please see response to reviewer 1, number 6.
3) The factor of CVVH or ECMO has not been mentioned. I am wondering if in the phase I of the study should add some more patients who are already in CHVVH. There may be an unexpected interaction there.
RESPONSE: See response to reviewer 1, number 7 regarding ECMO that has been added as an exclusion criteria. Regarding CVVH or other means of hemodialysis, issues can arise depending on the total dose of lipid and rate given. This has been described in the toxicologic literature, in which much larger amounts of intralipid are given rapidly for drug adsorption. 2 However, in cases in which lipid is given as total parenteral nutrition at a lower rate and dose (as in this study), this does not appear to be a significant issue. 3, 4 However, patients enrolled in the study who receive CVVH will be monitored for any issues and exclusion criteria can be adjusted if problems arise. 4) I have some concerns about the term "acute drop" of cholesterol. There are some patients that have already low levels of cholesterol. Should the authors exclude the malnourished patients? Maybe it is better not to talk about acute drop of cholesterol.
RESPONSE: We appreciate the reviewer's comment. Some of these patients will have levels that are low at enrollment (but not yet critically low) and continue to decline. In other cases, levels will be critically low at enrollment. In either case, it is hard to know the patient's baseline cholesterol levels, but it is likely based on our prior work and based on the enrollment cholesterol cutoffs that we have set, that this is due to the sepsis and does not represent the patient's baseline cholesterol levels. However, to address the reviewers comment, we have
changed the wording to focus on the reduced cholesterol levels that occur in early sepsis, rather than "drops" in cholesterol, since we do not know the baseline in some of these patients.
5)
The results of the study expect to give the answer which is the optimal dose for increasing cholesterol but not which is the optimal cholesterol levels. I am wondering if this is a problem for a pilot study. Furthermore, possibly the baseline levels of cholesterol may play a role for the increase in cholesterol; maybe it is easier to see an increase in cholesterol when baseline values are very low compared to values when are abnormal but more near to normal limits.
RESPONSE: We appreciate the reviewer's comment as it is an excellent point and one that we had considered. We have found from our previous study of changes in cholesterol levels over time, that the early changes in cholesterol levels (the delta) are more predictive than the baseline level itself, once that baseline level is below a particular threshold (100 mg/dL or HDL-C + LDL-C of < 70 mg/dL for inclusion in this study). For this reason, we chose to target cholesterol stabilization, or maintenance of cholesterol levels which when achieved, implies that the supply is meeting the metabolic demand. With regards to being easier to stabilize cholesterol levels in patients in whom values are very low at baseline, it is hard to know the answer to this question. From our own experience, we have found that patients with baseline critically low cholesterol levels are extremely sick and sometimes near death. In these cases, we have seen very low cholesterol levels at onset, drop to near undetectable levels at 48-hours when levels are rechecked. As this is a pilot study, our aim is to test feasibility of stabilizing cholesterol levels in this population but may not truly answer this question.
6) I think the expected/needed number of patients that would be included in the phase II study should be also mentioned.
RESPONSE: The sample size for this phase II pilot study is 48 patients, and is presented in the Sample Size and Data Analysis section.
If the reviewer is referring to the future, larger clinical trial, preliminary data from this pilot study will be needed to calculate the anticipated needed number of patients for that study.
Reviewer 3: Joe Alcock
1) The rationale and the proposed design of the study have important strengths and limitations. The study will be conducted in two centers, increasing the heterogeneity of patients enrolled in the study. However, the fact that both hospitals are part of the same medical system -University of Florida -make it only incrementally superior to a single centered trial. It is a randomized controlled trial, decreasing selection bias. However, it is not blinded to allocation of the intervention because blinding of a lipid infusion is not feasible.
RESPONSE:
The UF Gainesville and UF Jacksonville cohorts will be distinct in several ways. UF Gainesville patients will be recruited from the Surgical ICU, and not from the emergency department. UF Gainesville SICU patients more frequently acquire hospital-acquired sepsis, than community-acquired or healthcare associated sepsis as is commonly seen in UF Jacksonville emergency department patients. Second, the UF Gainesville patient population is socioeconomically and demographically different than UF Jacksonville patients. UF Gainesville patients are on average, middle-income, and are approximately 90% White. UF Jacksonville patients comprise a mostly urban, inner city patient population from a larger city, and are approximately 50% White, 50% black.
2) One important methodological issue is that the authors do not describe how nutrition will be measured or compared in this trial. Smoflipid is FDA approved as a parenteral source of nutrition. Even though the aim of Smoflipid in this study is to stabilize cholesterol, individuals receiving the experimental intervention will have likely have different nutritional requirements and fewer caloric needs, all else being equal, than controls. This potential confounder is not mentioned by the authors. I did not see a plan to measure or present the total nutrition received by both groups.
3) The evidence supporting the intervention in the background and discussion of this proposal can be criticized on several grounds. Other lipid emulsions have not been shown to improve outcomes in sepsis. For example, the LIPOS trial by Dellinger et al. . Failure of omega-3 to improve survival casts doubt on a benefit from anti-inflammatory omega-3 fatty acids in the present study. Of note, the rationale of the LIPOS trial was the ability of the lipid emulsion to bind endotoxin. This mechanism was also given in the present study. Unfortunately, the TLR4-endotoxin pathway has been extensively studied in sepsis and multiple interventions targeting that pathway have failed to improve outcomes (e.g. ACCESS trial of eritoran, Opal et al. JAMA 2016). In fact, no immunomodulatory intervention has ever durably improved survival in sepsis (e.g. Marshall 2014 Trends Mol Med).
RESPONSE: We appreciate the healthy skepticism of our intervention and the chance to respond. The clinical trial protocol that we have developed is based on data from our own prior work as well as concepts from the Dellinger et al LIPOS trial,
5 the work of Thomas Hall's group, 6, 7 and Keith Walley's group and work on LDL-receptors/PCKS9 and endotoxin clearance. 8, 9 There are two main concepts and drug effects of interest here that support the idea that Smoflipid may improve outcomes in sepsis. The first concept, cholesterol stabilization, has never been tested in a clinical trial to our knowledge. Stabilizing HDL-C, LDL-C, and triglycerides all have potential (though not proven) benefits. As mentioned in the article, there are numerous potential benefits to HDL-C, including the ability to bind and remove toxin, provide substrate to the adrenal glands for steroid synthesis, and prevent inflammatory cell migration. Similarly, Walley's group has shown that LDL-C is critical for removal of endotoxin from circulation via hepatic LDL receptors, a mechanism that would not have been tested in the LIPOS trial. Triglycerides are also capable of binding bacterial toxins. Though Smoflipid is different from Lipidose used in the LIPOS trial, it has a similar potential ability to bind and remove endotoxin, as endotoxin is lipid soluble and would get bound to cholesterol, transported to the liver for elimination and removed from the body (supports our choice of excluding patients with severe liver disease). The reviewer mentions that we adopted the inclusion/exclusion criteria of Parker et al, which is not entirely accurate. The only criteria adopted from Parker et al were the total bilirubin and albumin cut-offs, otherwise our criteria are based on our own prior work. In addition, the Parker study was of gram negative sepsis, and our study does not discriminate by infection type, as our research has shown that enhancing cholesterol function and levels may be beneficial to all infection types. As a separate note, we did actually try to obtain Lipidose to test its comparative efficacy to Smoflipid, but it is no longer available.
The second mechanism of interest is the fish oil component of Smoflipid, and this is partly supported by Hall's work that showed improvements in SOFA score over 7-days of ICU admission for patients receiving a pure fish oil emulsion. 6, 7 Our study using Smoflipid (fish oil plus other lipids) would achieve the same 0.2g/kg/day dose of fish oil as that administered in the Hall trial at a range of 1 to 1.3g/kg/day. Since our dose escalation study proposes to use doses starting at the same range (1g/kg up to 1.8g/kg) we expect similar anti-inflammatory effects. Fish oil has several beneficial effects, including blunting of the inflammatory response, reduction in cardiac arrhythmias, increased tissue microperfusion to name a few. 10 and reduce systemic inflammation after surgery and postoperative complications. 11, 12 We propose that lack of proof of benefit, is not the same as proof of lack of benefit. In such a case as this, we propose that further study is needed. In addition, lack of benefit in prior studies is now widely accepted to be potentially due to patient heterogeneity. 13 By limiting our study patients by cholesterol cut-offs, we are selecting patients who may be potential responders to this therapy and are reducing patient heterogeneity.
Some of the differences in positive vs. negative trials of fish oils may be attributed to route of administration (enteral vs. parenteral). For the purposes of a sepsis population, fish oil given parenterally takes effect within 1-3 hours, vs enterally which can take 1-3 days. The negative Lu et al paper quoted by the reviewer contained studies with mixed routes of administration (10 parenteral, and 7 enteral), with most studies having a high risk of bias, though it did show questionable reductions in ICU LOS and days on mechanical ventilation. Other studies have demonstrated that fish oil blunts the response to endotoxin in healthy volunteers,
4) Page 3 (top of page)
. Line 47. The assertion that "given that the study endpoint is numerical, the potential for bias is minimal" is incorrect. Systematic bias in the reporting of quantitative end-points is common and well-described. As an example, the post-hoc subgroup analysis (Parker et al. Crit Care 2014) referenced by the authors of this protocol was quantitative, but it might reflect publication biassince a negative post hoc result would not have been deemed worthy of interest or publication. The lack of concealment of allocation in this study remains an important, though not insurmountable, source of bias in this study.
RESPONSE:
We have changed the wording in the abstract to alleviate the reviewer's concern. We agree that bias is still a potential issue, and for this reason, we have mentioned that data abstractors will be blinded to study allocation (experimental vs. control group and drug dose). Unfortunately, we cannot control publication bias of the Parker study. RESPONSE: Reviewer 1 had a similar concern regarding this language. We have changed the wording to "may be" protective in response to the reviewers' comments. In the Guirgis et al study noted by the reviewer, that was a study of a different population of patients than what is being proposed in this clinical trial, and from the preliminary data used to determine our study interventions. The Guirgis et al study was a study of prospective cohort of communitydwelling adults who had cholesterol levels measured at a time when they were not sick. Those cholesterol levels, could have been months or even years prior to the onset of sepsis, and were used to determine the long-term risk of sepsis associated with baseline cholesterol levels. Measuring cholesterol levels during early sepsis is quite different, akin to measuring a lactate level when a person is healthy vs. critically ill with sepsis. It is hard, and probably inaccurate, to directly compare these values. Numerous studies have shown that baseline levels of HDL and LDL are predictive of clinical outcomes, the most notable being the studies by Chien et al, van Leeuwen et al, and Lagrost et al. [14] [15] [16] [17] We agree that causality remains unproven, though both human and animal studies have shown that HDL has the ability to protect against sepsis mechanistically. Our group has shown that reduced HDL-C levels may be related to the degree of inflammation. 18 We have also shown that impaired HDL function occurs in septic patients compared to healthy controls (reduced cholesterol efflux capacity) 19 and that reductions in HDL antioxidant function (paraoxonase-1 activity) differ among sepsis patients by outcome (early death, rapid recovery, or chronic critical illness). 20 6) Page 4. Line 29. "Numerous studies" should read "numerous observational trials" Page 5. Line 12. Here the authors introduce another potential mechanism -anti-inflammatory effect of omega-3 fish oil. This is despite the fact that no intervention based on immunomodulation has ever decreased mortality in sepsis (e.g. Marshall 2014 Trends Mol Med). RESPONSE: We have changed the wording. Please see response to Reviewer 3, comment 3 above regarding omega-3 fatty acids. 7) Page 5. Line 16. refers to the critical early period of sepsis when cholesterol levels reach a nadir. The problem is that patients will vary in their time to presentation for treatment from onset of symptoms. We will not know where a given patient is relative to the nadir in cholesterol.
We have removed the word nadir since the true nadir would not be known as the reviewer mentions. Our preliminary data, however, demonstrate significant differences in mortality in patients in whom cholesterol levels continue to drop vs. stabilize or rise in the early period (N= 223 patients, see Figure) . The relationship is strongest for LDL and total cholesterol levels. 8) Page 12. Line 31. I assume that the authors will perform statistical tests on HDL, LDL, and TC, so there are at least three variables in the lipid panel. For secondary end points, the authors will include many more variables, including at least 7 inflammatory biomarkers. Is there a plan to correct for multiple comparisons? This should be mentioned in the analysis plan. The authors should check whether they intend to compare the change in mean lipid levels, implying individual patients will be measured multiply at planned time points. Importantly, since lipids are drawn at five planned collection times, limiting the analysis to only two time points leaves out the remaining three. Thus, the proposed analysis plan ignores data that they plan to collect and limits the ability to uncover a difference if it exists (increasing the likelihood of type II error). To avoid that problem the authors might use a statistical test more appropriate for repeated measures, such as a linear mixed model.
The primary outcome is 48-hour total cholesterol levels. Other main secondary outcomes include 7-day total cholesterol levels, 48-hours SOFA score, and 7-day SOFA score. The trial will be considered a positive trial if it achieves the primary outcome, and a negative trial if it does not. The reason for collecting more data than what will be used for the primary or main secondary outcomes is to inform a later, larger trial should one be pursued. If necessary, repeated measures ANOVA can be used for within group comparisons. 9) Page 13. Line 14. "secondary analysis" should read a "secondary post-hoc analysis" or "secondary subgroup analysis that was not a pre-specified subgroup in the original study" RESPONSE: This has been changed. 10) Page 13 Line 18. "demonstrated mortality reductions," should be "showed potential reduced mortality." RESPONSE: This has been changed.
